Belimumab With Standard Therapy Proves Beneficial in Lupus Nephritis

September 18, 2020

In today’s one-on-one interview, we talk with Dr. Richard Furie who is chief of rheumatology at Northwell Health in New York. Dr. Furie is the lead investigator of a study on lupus nephritis just published in the New England Journal of Medicine. Dr. Furie and colleagues from the Feinstein Institutes for Medical Research reported that belimumab with standard therapy has been shown to be an effective treatment for lupus nephritis. If the treatment is approved by the U.S. Food and Drug Administration, it would be the first of its kind for this condition. In this presentation, Dr. Furie tell us more.

CITATION: Richard Furie, M.D., Brad H. Rovin, M.D., Frédéric Houssiau, M.D., Ph.D., et al. "Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis," New England Journal of Medicine. Sept. 17, 2020. DOI: 10.1056/NEJMoa2001180